Cargando…

Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients

Malignant pleural mesothelioma (MPM) is an aggressive cancer with an increasing incidence, poor prognosis and limited effective treatment options. Hence, new treatment strategies are warranted which include immune checkpoint blockade approaches with encouraging preliminary data. Research on the immu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marcq, Elly, Waele, Jorrit De, Audenaerde, Jonas Van, Lion, Eva, Santermans, Eva, Hens, Niel, Pauwels, Patrick, van Meerbeeck, Jan P., Smits, Evelien L.J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685704/ https://www.ncbi.nlm.nih.gov/pubmed/29163783 http://dx.doi.org/10.18632/oncotarget.21113

Ejemplares similares

The Search for an Interesting Partner to Combine with PD-L1 Blockade in Mesothelioma: Focus on TIM-3 and LAG-3
por: Marcq, Elly, et al.
Publicado: (2021)

Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma: Investigating the Effect of Chemotherapy on Immune Checkpoint Expression
por: Marcq, Elly, et al.
Publicado: (2019)

Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells
por: Van Audenaerde, Jonas R.M., et al.
Publicado: (2017)

Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma
por: Rovers, Sophie, et al.
Publicado: (2022)

Cold Atmospheric Plasma-Treated PBS Eliminates Immunosuppressive Pancreatic Stellate Cells and Induces Immunogenic Cell Death of Pancreatic Cancer Cells
por: Van Loenhout, Jinthe, et al.
Publicado: (2019)

The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma
por: Chen, Benjamin J., et al.
Publicado: (2019)

PD-L1, PD-1, LAG-3, and TIM-3 in Melanoma: Expression in Brain Metastases Compared to Corresponding Extracranial Tumors
por: Wang, Jaeyun Jane, et al.
Publicado: (2019)

Immune Checkpoint Profiling in Humanized Breast Cancer Mice Revealed Cell-Specific LAG-3/PD-1/TIM-3 Co-Expression and Elevated PD-1/TIM-3 Secretion
por: Bruss, Christina, et al.
Publicado: (2023)

Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors
por: Natoli, Marina, et al.
Publicado: (2022)

Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update
por: Verhoeven, Yannick, et al.
Publicado: (2021)

Combined inhibition of PD-1/PD-L1, Lag-3, and Tim-3 axes augments antitumor immunity in gastric cancer–T cell coculture models
por: Mimura, Kosaku, et al.
Publicado: (2021)

Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4(+) T Cells
por: Saleh, Reem, et al.
Publicado: (2019)

PD-1, TIM-3, and LAG-3 Expression in T Cells in a Patient with Recurrent Ossifying Fibroma: A Case Report
por: García-Muñoz, Alejandro, et al.
Publicado: (2020)

The CD70-CD27 axis in oncology: the new kids on the block
por: Flieswasser, Tal, et al.
Publicado: (2022)

Novel combination immunotherapy for pancreatic cancer: potent anti‐tumor effects with CD40 agonist and interleukin‐15 treatment
por: Van Audenaerde, Jonas RM, et al.
Publicado: (2020)

DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer
por: Sasidharan Nair, Varun, et al.
Publicado: (2018)

Systemic levels of the soluble co-inhibitory immune checkpoints, CTLA-4, LAG-3, PD-1/PD-L1 and TIM-3 are markedly increased in basal cell carcinoma
por: Malinga, Nonkululeko Z., et al.
Publicado: (2022)

Clinically Relevant Chemotherapeutics Have the Ability to Induce Immunogenic Cell Death in Non-Small Cell Lung Cancer
por: Flieswasser, Tal, et al.
Publicado: (2020)

Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade
por: Tian, Tian, et al.
Publicado: (2021)

Simultaneous Genetic Ablation of PD-1, LAG-3, and TIM-3 in CD8 T Cells Delays Tumor Growth and Improves Survival Outcome
por: Ciraolo, Elisa, et al.
Publicado: (2022)

Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

NTRK Fusions in Sarcomas: Diagnostic Challenges and Clinical Aspects
por: Siozopoulou, Vasiliki, et al.
Publicado: (2021)

PD-1、TIM-3、LAG-3、BTLA在结外NK/T细胞淋巴瘤中的表达及其预后价值
Publicado: (2021)

The Role of TIM-3 and LAG-3 in the Microenvironment and Immunotherapy of Ovarian Cancer
por: Kozłowski, Mateusz, et al.
Publicado: (2022)

Correction: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

Immune Checkpoint Inhibitory Therapy in Sarcomas: Is There Light at the End of the Tunnel?
por: Siozopoulou, Vasiliki, et al.
Publicado: (2021)

Immune Co-inhibitory Receptors CTLA-4, PD-1, TIGIT, LAG-3, and TIM-3 in Upper Tract Urothelial Carcinomas: A Large Cohort Study
por: Jin, Shengming, et al.
Publicado: (2023)

DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer
por: Sasidharan Nair, Varun, et al.
Publicado: (2018)

Expression of the immune checkpoint receptors PD-1, LAG3, and TIM3 in the immune context of stage II and III gastric cancer by using single and chromogenic multiplex immunohistochemistry
por: Park, Yujun, et al.
Publicado: (2021)

High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer
por: Mollavelioglu, Baran, et al.
Publicado: (2022)

Elevation of Tim-3 and PD-1 Expression on T Cells Appears Early in HIV Infection, and Differential Tim-3 and PD-1 Expression Patterns Can Be Induced by Common γ-Chain Cytokines
por: Zhang, Zi-Ning, et al.
Publicado: (2015)

LAG3-PD-1 Combo Overcome the Disadvantage of Drug Resistance
por: Wei, Yiming, et al.
Publicado: (2022)

Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer
por: Versteven, Maarten, et al.
Publicado: (2018)

Elevated Levels of Soluble CTLA-4, PD-1, PD-L1, LAG-3 and TIM-3 and Systemic Inflammatory Stress as Potential Contributors to Immune Suppression and Generalized Tumorigenesis in a Cohort of South African Xeroderma Pigmentosum Patients
por: Kgokolo, Mahlatse C. M., et al.
Publicado: (2022)

A BIVALENT TIM-3/PD-1 BISPECIFIC ANTIBODY FOR THE TREATMENT OF PD-1 ANTIBODY RESISTANT OR REFRACTORY SOLID TUMORS
por: Luan, Yan, et al.
Publicado: (2023)

PD-1 and Tim-3 Pathways Regulate CD8(+) T Cells Function in Atherosclerosis
por: Qiu, Ming-Ke, et al.
Publicado: (2015)

PD‐1+ TIM‐3+ T cells in malignant ascites predict prognosis of gastrointestinal cancer
por: Nakano, Michitaka, et al.
Publicado: (2018)

PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy
por: Zahm, Christopher D., et al.
Publicado: (2021)

The Role of the Immune Checkpoint Molecules PD-1/PD-L1 and TIM-3/Gal-9 in the Pathogenesis of Preeclampsia—A Narrative Review
por: Mittelberger, Johanna, et al.
Publicado: (2022)

The extent of metalloproteinase-mediated LAG3 cleavage limits the efficacy of PD1 blockade
por: Andrews, Lawrence P, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_r7vir7uovebc2dgehe6l2hmosb